Deep Track Capital LP Boosts Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Deep Track Capital LP increased its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 151.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,000,000 shares of the company's stock after acquiring an additional 1,203,148 shares during the quarter. Bicara Therapeutics comprises approximately 1.3% of Deep Track Capital LP's portfolio, making the stock its 26th biggest position. Deep Track Capital LP owned 3.68% of Bicara Therapeutics worth $34,840,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. boosted its stake in shares of Bicara Therapeutics by 171.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock valued at $37,893,000 after purchasing an additional 1,375,265 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Bicara Therapeutics by 1,457.9% during the 4th quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company's stock worth $18,997,000 after acquiring an additional 1,020,528 shares during the period. Foresite Capital Management VI LLC bought a new position in shares of Bicara Therapeutics in the 4th quarter worth approximately $16,549,000. Acorn Capital Advisors LLC purchased a new position in shares of Bicara Therapeutics in the 4th quarter valued at approximately $11,208,000. Finally, Geode Capital Management LLC boosted its position in shares of Bicara Therapeutics by 859.4% during the fourth quarter. Geode Capital Management LLC now owns 466,642 shares of the company's stock valued at $8,131,000 after purchasing an additional 418,003 shares in the last quarter.

Bicara Therapeutics Stock Performance

BCAX traded down $0.23 during trading on Friday, hitting $12.90. 729,786 shares of the company's stock traded hands, compared to its average volume of 487,077. The company's 50 day simple moving average is $12.95 and its two-hundred day simple moving average is $15.61. Bicara Therapeutics Inc. has a 12-month low of $8.91 and a 12-month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08). Research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BCAX shares. Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. HC Wainwright dropped their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Wells Fargo & Company began coverage on shares of Bicara Therapeutics in a research note on Thursday, April 17th. They set an "underweight" rating and a $8.00 target price for the company. Wedbush reissued an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $32.43.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.